Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare reimbursement shifts, intricate lab test coding, and a steady stream of acquisitions make Quest Diagnostics� disclosures anything but light reading. If you have ever Googled, “How to read Quest Diagnostics� 10-K annual report� or “Quest Diagnostics SEC filings explained simply,� you already know each report buries critical payer-mix data, segment margins, and CLIA compliance notes inside hundreds of pages.
Stock Titan’s AI-powered analysis turns that maze into a map. Every Quest Diagnostics annual report 10-K simplified, each Quest Diagnostics quarterly earnings report 10-Q filing distilled into revenue drivers, and all Quest Diagnostics 8-K material events explained appear here the moment EDGAR posts. Ask, “What does Quest Diagnostics report in their SEC filings?� and you’ll find plain-English summaries, red-flag alerts, and linked schedules. Our dashboard even flags the Quest Diagnostics proxy statement executive compensation tables so pay packages can be reviewed alongside performance trends.
Keeping tabs on leadership confidence? We surface Quest Diagnostics insider trading Form 4 transactions and deliver Quest Diagnostics Form 4 insider transactions real-time so you never miss a trade. Use the platform to:
- Compare revenue swings between Diagnostic Information Services and Drug Monitoring segments
- Review Quest Diagnostics earnings report filing analysis with AI commentary
- Track Quest Diagnostics executive stock transactions Form 4 ahead of material announcements
From understanding Quest Diagnostics SEC documents with AI to spotting compliance risks before they hit the headlines, our comprehensive coverage and real-time alerts provide the clarity professionals need.
Clarivate Plc (CLVT) � Form 4 insider transaction filed 07/02/2025.
Director Andrew M. Snyder reported routine quarterly equity compensation in lieu of a cash retainer. On 06/30/2025 he acquired 11,918 ordinary shares at the 06/30/2025 closing price of $4.30, equivalent to the $51,250 board fee. To cover withholding taxes, 527 shares were surrendered at the same price. After these transactions Mr. Snyder holds 164,489 shares directly.
In addition, Snyder has large indirect holdings totalling 24,374,148 shares through Cambridge Information Group entities and a family trust, though he disclaims beneficial ownership beyond his pecuniary interest.
No options or other derivative securities were reported. The filing reflects normal director compensation rather than a discretionary open-market purchase, so market impact is expected to be minimal.
Quest Diagnostics has filed an S-3ASR shelf registration statement to offer debt securities from time to time. This automatic shelf registration allows the company, as a large accelerated filer, to issue various debt instruments with terms to be specified in future prospectus supplements.
Key aspects of the filing include:
- The registration is effective immediately upon filing under Rule 462(e)
- Securities will be offered on a delayed or continuous basis under Rule 415
- Specific terms, pricing, and distribution methods will be detailed in future prospectus supplements
- The company maintains status as a large accelerated filer
The filing includes detailed risk factors related to:
- Healthcare industry competition and pricing pressures
- Regulatory compliance and potential government investigations
- Integration risks from acquisitions
- Cybersecurity and technological disruption threats
- Economic conditions and healthcare reform impacts
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
What is the primary business of Quest Diagnostics Inc?
How does Quest Diagnostics generate revenue?
What sets Quest Diagnostics apart in the diagnostic testing industry?
How extensive is Quest Diagnostics� laboratory network?
What role does innovation play at Quest Diagnostics?
How does Quest Diagnostics support research and scientific advancements?
What quality control measures does Quest Diagnostics implement?
In what ways has Quest Diagnostics expanded through strategic acquisitions?
